CC BY-NC-ND 4.0 · Laryngorhinootologie 2019; 98(S 02): S77-S78
DOI: 10.1055/s-0039-1686034
Abstracts
Oncology

Immune Checkpoint expression on lymphocyte subsets may depend on HLA-Type of patients with head neck squamous cell carcinoma (HNSCC)

D Mytilineos
1   HNO-Klinik, Kopf-Hals-Chirurgie, Universitätsklinikum Ulm, Ulm
,
A Grages
2   HNO-Forschungslabor, Universitätsklinikum Ulm, Ulm
,
PJ Schuler
1   HNO-Klinik, Kopf-Hals-Chirurgie, Universitätsklinikum Ulm, Ulm
,
S Jeske
2   HNO-Forschungslabor, Universitätsklinikum Ulm, Ulm
,
L Puntigam
2   HNO-Forschungslabor, Universitätsklinikum Ulm, Ulm
,
C Brunner
2   HNO-Forschungslabor, Universitätsklinikum Ulm, Ulm
,
J Mytilineos
3   IKT Ulm, DRK Baden Wuerttemberg – Hessen und Uniklinik Ulm, Ulm
,
TK Hoffmann
1   HNO-Klinik, Kopf-Hals-Chirurgie, Universitätsklinikum Ulm, Ulm
,
S Laban
1   HNO-Klinik, Kopf-Hals-Chirurgie, Universitätsklinikum Ulm, Ulm
› Institutsangaben
 

Introduction:

Inhibitory immune checkpoints like „Cytotoxic T-Lymphocyte Antigen 4“ (CTLA4) and „Programmed Cell Death-1“ (PD-1) are important targets for immunotherapy. However, T-cell activation requires antigen presentation by Human-Leukocyte-Antigens (HLA). Because of the peptide restriction of HLA-class I molecules the presented antigens are dependent on the HLA genotype. Therefore, the expression of inhibitory checkpoints may differ depending on the HLA-type. The aim of this study was to analyze immune checkpoint expression on different lymphocyte subsets in association with HLA factors.

Methods:

Within prospective, non-interventional studies, 42 HNSCC patients were HLA-typed by next generation sequencing. Immune checkpoint expression was analyzed with flow cytometry. Based on the findings published by Wichman et al. patients were grouped by HLA-alleles with positive and negative impact on progression free survival (PFS). Immune checkpoint expression in various lymphocyte subsets were then compared for the two HLA-predictor groups.

Result:

Our data showed a significantly increased CTLA4-expression on CD4- and CD8-positive T cells as well as CD39-positive regulatory T cells in patients with predominantly positive prognostic HLA alleles compared to those with predominantly negative HLA-alleles.

Conclusion:

The increased CTLA4-expression on lymphocytes among patients with good prognosis HLA-types could be a hint for the presence of suppressed cancer immunity. Identification of the presented antigens and further confirmatory functional tests are needed.



Publikationsverlauf

Publikationsdatum:
23. April 2019 (online)

© 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Stuttgart · New York